Published : 15 May 2023
Aagami has been appointed by a Pennsylvania Pharma to support their strategic partnering needs.
Client is a Biopharma R&D focused company that has developed 6-Shogaol - a “New Drug Category” characterized by a “Smart Drug” mechanism of action, that shows promise in preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia. The asset is currently in Phase 2.
6-Shogaol is phenolic compound extracted from Ginger. Ginger, the rhizome of the plant Zingiber officinale exhibits antioxidant, anti-inflammatory, and anti-tumor activities. The shogaols are formed by dehydration at the C-5 and C-4 of gingerols during thermal processing.
Aagami shall assist the client in exploring potential business opportunities with companies that may be interested in entering into commercial arrangements that may include Product Sale/ Strategic relationship/ Partnership/Investment and other forms of partnering with respect to Client’s assets, products and/or technologies.
If you would like to know more about this partnering opportunity, please contact us for a non-confidential presentation.